MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$312,851K
Free Cash flow
-$142,033K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Maturities and sales of short-te...
Proceeds from the issuance of co...
Accrued liabilities
Others
Negative Cash Flow Breakdown
Purchase of short-term investmen...
Net loss
Prepaid expenses and other curre...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-215,700
-189,424
-219,172
-231,793
Non-cash interest expense
-
-
0
-
Amortization of discount on short-term investments
2,969
4,217
3,017
0
Unrealized foreign exchange loss (gain)
-30
-190
-94
-49
Reclassification of currency translation gain
-
-
0
-
Impairment of fixed assets
-
-
0
-
Depreciation
46
44
42
42
Stock-based compensation
68,706
72,791
111,779
130,761
Loss on disposal of assets
-
-
0
-
Acquired in-process research and development expense
-
-
0
0
Prepaid expenses and other current assets
12,032
11,014
-1,208
-3,739
Other assets
217
1,026
347
856
Accounts payable
-3,907
6,802
-2,145
-839
Accrued liabilities
20,737
12,218
5,533
945
Accrued compensation
2,370
-7,852
3,956
4,360
Other current liabilities
1,474
-1,269
-
476
Other non-current liabilities
3
-33
-2
30
Operating lease right-of-use assets and lease liabilities, net
335
365
267
-64
Net cash used in operating activities
-141,124
-122,291
-101,938
-93,080
Maturities and sales of short-term investments
448,795
177,293
0
0
Purchase of short-term investments
224,990
177,286
484,993
0
Purchases of property and equipment
909
245
164
71
Proceeds from sale of property, plant and equipment
-
-
0
-
Payments to akeso for upfront milestone payments and associated direct transaction costs
-
-
0
0
Proceeds from issuance of common stock-Rights Offering
-
-
0
-
Net cash provided by investing activities
222,896
-238
-485,157
-71
Transaction costs from the issuance of common stock for rights offering
-
-
0
-
Proceeds from the issuance of common stock via private placements, net of offering costs
-
-
500,037
0
Re-payment of related party promissory notes
-
-
0
0
Proceeds from the issuance of common stock under at-the-market offering, net of commissions
227,413
-
-
-
Proceeds from issuance of common stock-At Market Offering
-
-
72,764
31,764
Proceeds received related to employee stock purchase plan and exercise of stock options
3,665
3,797
1,020
2,049
Proceeds from exercise of warrants
0
0
0
0
Net cash provided by financing activities
231,078
3,797
573,821
33,813
Effect of exchange rate changes on cash
1
-19
-19
22
Increase in cash, cash equivalents and restricted cash
312,851
-118,751
-13,293
-59,316
Cash, cash equivalents and restricted cash at beginning of period
106,831
225,582
211,844
211,844
Cash, cash equivalents and restricted cash at end of period
419,682
106,831
225,582
238,875
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from the
issuance of common stock...
$227,413K
Proceeds received
related to employee...
$3,665K
(548.67%↑ Y/Y)
Maturities and sales of
short-term investments
$448,795K
(197.59%↑ Y/Y)
Net cash provided by
financing activities
$231,078K
(10299.55%↑ Y/Y)
Net cash provided by
investing activities
$222,896K
(47.80%↑ Y/Y)
Effect of exchange rate
changes on cash
$1K
(-98.36%↓ Y/Y)
Canceled cashflow
$225,899K
Increase in cash, cash
equivalents and restricted...
$312,851K
(262.32%↑ Y/Y)
Canceled cashflow
$141,124K
Purchase of short-term
investments
$224,990K
Purchases of property and
equipment
$909K
Stock-based compensation
$68,706K
(-85.65%↓ Y/Y)
Accrued liabilities
$20,737K
(328.36%↑ Y/Y)
Accrued compensation
$2,370K
(8.67%↑ Y/Y)
Other current
liabilities
$1,474K
(109.38%↑ Y/Y)
Operating lease
right-of-use assets and lease...
$335K
(452.63%↑ Y/Y)
Depreciation
$46K
(24.32%↑ Y/Y)
Unrealized foreign
exchange loss (gain)
-$30K
(-112.55%↓ Y/Y)
Other non-current
liabilities
$3K
(-88.89%↓ Y/Y)
Net cash used in
operating activities
-$141,124K
(-111.44%↓ Y/Y)
Canceled cashflow
$93,701K
Net loss
-$215,700K
(61.87%↑ Y/Y)
Prepaid expenses and
other current assets
$12,032K
(523.10%↑ Y/Y)
Accounts payable
-$3,907K
(-121.79%↓ Y/Y)
Amortization of discount on
short-term investments
$2,969K
(190.22%↑ Y/Y)
Other assets
$217K
(-90.37%↓ Y/Y)
Buy us a coffee
summitplc-logo_05fd32df-svg
Summit Therapeutics Inc. (SMMT)
summitplc-logo_05fd32df-svg
Summit Therapeutics Inc. (SMMT)